Unaudited Condensed Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 28, 2014	Sep. 29, 2013
Cash flows from operating activities:
Net income	$ 49,141	$ 43,785
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	26,398	23,745
Purchase premium amortization/discount accretion on investments, net	42	878
Non-cash stock-based compensation	15,226	12,492
Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net	(394)	483
Excess tax benefit from stock-based compensation	(340)	(665)
Impairment charges	0	2,000
Deferred income taxes	(2,133)	(4,381)
Changes in assets and liabilities, net of effect of acquisitions:
Accounts receivable	(12,084)	(13,951)
Inventories	17,963	(33,499)
Prepaid expenses and other assets	(9,846)	(8,795)
Accounts payable	(22,439)	40,993
Accrued employee compensation	4,021	(1,153)
Other accrued liabilities	(9,196)	8,721
Deferred revenue	9,221	404
Income taxes payable	1,974	1,737
Net cash provided by operating activities	67,554	72,794
Cash flows from investing activities:
Purchases of short-term investments	(105,076)	(128,322)
Proceeds from sales and maturities of short-term investments	109,669	214,341
Purchase of property and equipment	(13,421)	(11,709)
Payments for patents	0	(275)
Proceeds from sale of cost method investment	0	3,890
Payments made in connection with business acquisitions	(1,050)	(147,215)
Net cash used in investing activities	(9,878)	(69,290)
Cash flows from financing activities:
Purchase and retirement of treasury stock	(68,006)	(486)
Proceeds from exercise of stock options	6,039	5,630
Proceeds from issuance of common stock under employee stock purchase plan	2,762	2,139
Excess tax benefit from stock-based compensation	340	665
Net cash (used in) provided by financing activities	(58,865)	7,948
Net (decrease) increase in cash and cash equivalents	(1,189)	11,452
Cash and cash equivalents, at beginning of period	143,009	149,032
Cash and cash equivalents, at end of period	$ 141,820	$ 160,484